ライフサイエンスコーパス: epinephrine

1 (0.5% L-bupivacaine and 1.5% lidocaine with epinephrine).

2 ed AEs, 59% with antihistamines and 12% with epinephrine.

3 al immunotherapy and some require injectable epinephrine.

4 Thirteen patients (6.7%) required injectable epinephrine.

5 re laryngopharyngeal disorders and no use of epinephrine.

6 der medical supervision and was treated with epinephrine.

7 nition of loss of pulse to the first dose of epinephrine.

8 kable rhythm who received at least 1 dose of epinephrine.

9 and vasopressin alone or in combination with epinephrine.

10 rotransmitters dopamine, norepinephrine, and epinephrine.

11 treatment, and the cardiovascular effects of epinephrine.

12 n plus intrathoracic pressure regulator plus epinephrine.

13 opharynx, with no severe symptoms or uses of epinephrine.

14 e, plasma cortisol, prolactin, oxytocin, and epinephrine.

15 t was not responsive to electrical shocks or epinephrine.

16 stress was modeled by sustained delivery of epinephrine.

17 and 0.23 (95% CI: 0.14 to 0.37) for >5 mg of epinephrine.

18 CI, 0.78-0.99) when compared with high dose epinephrine.

19 04% were severe, and 0.08% subjects received epinephrine.

20 the electrochemical sensing of dopamine and epinephrine.

21 oral antihistamines only, and none received epinephrine.

22 Advanced life support always included IV epinephrine (0.05 mug/kg).

23 receive either dopamine (5-10 mug/kg/min) or epinephrine (0.1-0.3 mug/kg/min) through a peripheral or

24 nce interval [CI]: 0.27 to 0.84) for 1 mg of epinephrine, 0.30 (95% CI: 0.20 to 0.47) for 2 to 5 mg o

25 und guidance, 20-25 mL of 0.25% bupivacaine (epinephrine 1:400 000) were injected near the triangles-

26 After 4 to 13 weeks, epinephrine (1 mug kg(-1) min(-1)) was infused, and the

27 ,556 eligible patients, 1,134 (73%) received epinephrine; 194 (17%) of these patients had a good outc

28 n therapy (1D-2D), and norepinephrine and/or epinephrine (1D).

29 -enhanced cardiopulmonary resuscitation plus epinephrine (24+/-6 min, 63+/-8 min, and 50+/-9 min, res

30 mine (11)C-hydroxyephedrine was smaller than epinephrine (41 +/- 8 vs. 47% +/- 6% of left ventricle,

31 ive to metabolic degradation, was similar to epinephrine (48 +/- 6 vs. 47% +/- 6%, P = 0.011 vs. perf

32 t incubation of normal RBCs and SS-RBCs with epinephrine, a catecholamine that binds to the beta-adre

33 io of receiving each medication in 2016 were epinephrine (adjusted odds ratio, 1.5; 95% CI, 1.3-1.8),

34 ntify hospital variation in rates of delayed epinephrine administration (>5 minutes) and its associat

35 ates of timely defibrillation (<=2 minutes), epinephrine administration (<=5 minutes), survival to di

36 les, compared to without, had lower rates of epinephrine administration (incidence rate per 10,000 st

37 ded the initial timing and dose intervals of epinephrine administration (new treatment recommendation

38 the extent of hospital variation in delayed epinephrine administration and its effect on hospital-le

39 elation between a hospital's rate of delayed epinephrine administration and its risk-standardized rat

40 tion and potential allergic reactions (using epinephrine administration as a surrogate event) after A

41 Studies on epinephrine administration as bolus (e.g., during cardio

42 ributable to nonshockable rhythms, delays in epinephrine administration beyond 5 minutes is associate

43 Epinephrine administration by bolus resulted in transien

44 t, the initial timing and dose intervals for epinephrine administration during resuscitation, and the

45 Delays in epinephrine administration following in-hospital cardiac

46 e effect of peanut-free policies on rates of epinephrine administration for allergic reactions in Mas

47 Hospitals with high rates of delayed epinephrine administration had lower rates of overall su

48 Our study showed that although continuous epinephrine administration had no significant impact on

49 etrospective study, we analyzed (1) rates of epinephrine administration in all Massachusetts public s

50 Patients with time to epinephrine administration of longer than 5 minutes (233

51 ntrolled trials to investigate the effect of epinephrine administration on outcome of critically ill

52 having peanut-free classrooms did not affect epinephrine administration rates.

53 Longer time to epinephrine administration was also associated with decr

54 Longer time to epinephrine administration was associated with lower ris

55 The odds of delay in epinephrine administration were 58% higher at 1 randomly

56 Rates of epinephrine administration were compared for schools wit

57 The odds of C difficile infection and epinephrine administration were significantly higher amo

58 er improving hospital performance on time to epinephrine administration, especially at hospitals with

59 al associated with timely defibrillation and epinephrine administration, these findings provide impor

60 hospital rates of timely defibrillation and epinephrine administration.

61 c arrest, cardiopulmonary resuscitation, and epinephrine administration.

62 Epinephrine (adrenaline) treatment is underused in healt

63 ion in both preterm and term infants, use of epinephrine (adrenaline) when ventilation and compressio

64 ontrolled trial showed that standard dose of epinephrine also improved survival at 30 days and 3 mont

65 Treatment with epinephrine also reduced the systemic accumulation of bo

66 sulted in a 37% increase in plasma levels of epinephrine and a 44% increase in plasma norepinephrine

67 ulinum antitoxin recipients and will require epinephrine and antihistamine treatment and, possibly, i

68 Epinephrine and antihistamines followed by systemic cort

69 Current treatments for allergies include epinephrine and antihistamines, which treat the symptoms

70 Following epinephrine and caffeine, only the R67Q(+/-) mice had bi

71 say utility, we exposed embryos to the drugs epinephrine and clonidine, which increased or decreased

72 Thus, the stress-related hormones epinephrine and corticosterone selectively modulate acut

73 hat autonomic neurons are more responsive to epinephrine and corticosterone than are sensory neurons,

74 e neuronal cultures with the stress hormones epinephrine and corticosterone.

75 r hypoglycemia symptom scores and had higher epinephrine and cortisol responses compared with the una

76 the relationship between pre-hospital use of epinephrine and functional survival among patients with

77 impaired glucose sensing, noted by impaired epinephrine and glucagon responses and impaired c-fos ac

78 Therefore, the increased epinephrine and glucagon secretion with declining plasma

79 cogen that markedly elevated the response of epinephrine and glucagon to a given hypoglycemia and inc

80 ds, and more recently with nebulized racemic epinephrine and hypertonic saline.

81 alyzes the final step in the biosynthesis of epinephrine and is a potential drug target, primarily fo

82 Epinephrine and norepinephrine are present in the pro-ur

83 This study reveals epinephrine and norepinephrine as novel regulators of ce

84 hesis, which results in dopamine, serotonin, epinephrine and norepinephrine deficiencies.

85 Catecholamines such as epinephrine and norepinephrine promote energy expenditur

86 Both circulating epinephrine and norepinephrine released from adrenal med

87 to, and the cardiac and vascular response to epinephrine and norepinephrine underlies optimal managem

88 responses to the hormones/neurotransmitters epinephrine and norepinephrine which are found in the ne

89 ources of enteric neurotransmitters, such as epinephrine and norepinephrine, that are known to increa

90 om chromaffin cells, produce catecholamines, epinephrine and norepinephrine.

91 Delayed administration of epinephrine and upright posture are situational risk fac

92 erences in outcomes between standard dose of epinephrine and vasopressin alone or in combination with

93 expressed adrenergic receptors (activated by epinephrine) and the glucocorticoid receptor (activated

94 0.30 (95% CI: 0.20 to 0.47) for 2 to 5 mg of epinephrine, and 0.23 (95% CI: 0.14 to 0.37) for >5 mg o

95 d epinephrine content and circulating plasma epinephrine, and decreased adrenal CgB.

96 and elevation of circulating corticosterone, epinephrine, and glucose.

97 l animals required significantly more fluid, epinephrine, and higher final pump flow while having low

98 r blockers (ARBs), beta-adrenergic blockers, epinephrine, and Kounis syndrome.

99 olamine neurotransmitters, including L-DOPA, epinephrine, and norepinephrine.

100 ment of the hybrid ( S)-22, the full agonist epinephrine, and the beta(2)-selective, G protein-biased

101 equired, the administration of standard-dose epinephrine, and the decisions involved in the applicati

102 erall, 13 213 (12.7%) patients had delays to epinephrine, and this rate varied markedly across hospit

103 its treatment is delayed, with little use of epinephrine; and its underlying cause or causes are poor

104 of epinephrine to placebo, high or low dose epinephrine, any other vasopressor alone or in combinati

105 neurologic effects on patients treated with epinephrine are not well understood.

106 e to LAMA5, and insignificant stimulation by epinephrine as compared to SS-RBCs from untreated patien

107 showed that continuous IV administration of epinephrine as inotropic/vasopressor agent is not associ

108 n plus epinephrine groups received 0.5 mg of epinephrine at 4.5 and 9 minutes of cardiopulmonary resu

109 neurotransmitters (melatonin, serotonin, and epinephrine) at various concentrations followed by the S

110 riencing anaphylaxis nor being prescribed an epinephrine auto-injector (EAI) contributed to impairmen

111 While 94% of patients took an epinephrine auto-injector (EAI) into risky situations, o

112 en, and to establish the trend of prescribed epinephrine auto-injectors (EAI) among paediatric popula

113 of symptomatic medications that may include epinephrine auto-injectors.

114 Patients at risk should always carry an epinephrine autoinjector (EAI).

115 uary 2011 and March 2017 and were prescribed epinephrine autoinjector (EpiPen((R))) for treatment wer

116 nut allergy relies on allergen avoidance and epinephrine autoinjector for rescue treatment in patient

117 Patients should possess an epinephrine autoinjector with an anaphylaxis self-manage

118 y treated, of which 10% were treated with an epinephrine autoinjector.

119 No epinephrine autoinjectors contain an optimal dose for in

120 e allergic reactions with antihistamines and epinephrine autoinjectors.

121 kable rhythm who received at least 1 dose of epinephrine between 2000 and 2014.

122 ant impact on overall cerebral hemodynamics, epinephrine boluses transiently improved cerebral oxygen

123 The physiologic stimuli, glucagon and epinephrine, both increased hepatic glucose production,

124 in response to adenosine 5'-diphosphate and epinephrine, but variable aggregation defects with other

125 ponse to arachidonic acid, ADP, collagen, or epinephrine by optical aggregometry.

126 cells, increased adrenal norepinephrine and epinephrine content and circulating plasma epinephrine,

127 ratio = 1.41; 95% CI, 1.01-1.96; p = 0.04), epinephrine cumulate dose less than or equal to 3 mg (ha

128 Stress-related mediators (eg, epinephrine) decrease this threshold, leading to autopha

129 ut not neurologic outcomes, standard dose of epinephrine decreased return of spontaneous circulation

130 Time to epinephrine, defined as time in minutes from recognition

131 5.4%) at hospitals in the lowest quartile of epinephrine delay, risk-standardized survival was 16% lo

132 an initial nonshockable rhythm who received epinephrine, delay in administration of epinephrine was

133 als in the quartile with the highest rate of epinephrine delays (10.8%; interquartile range, 9.7%-12.

134 circumferential distribution following local epinephrine delivery from a distributed source to the en

135 ction efficiency can be successfully used in epinephrine detection for filtering out signals from asc

136 Our results suggest that the effects of epinephrine diminish with successive boluses as the impa

137 influence on brain levels of norepinephrine, epinephrine, dopamine, serotonin and their metabolites,

138 tion (OR: 0.31; 95% CI: 0.19 to 0.51), lower epinephrine dosage (OR: 0.47; 95% CI: 0.25 to 0.87), and

139 Delay in administration of the first epinephrine dose is associated with decreased survival a

140 lopment of autoinjectors containing a 0.1-mg epinephrine dose suitable for infants, and inclusion of

141 The median time to first epinephrine dose was 1 minute (IQR, 0-4; range, 0-20; me

142 iopulmonary resuscitation, episode location, epinephrine dose, emergency medical services response ti

143 with standard advanced cardiac life support epinephrine dosing (Guideline care).

144 We further hypothesized that the addition of epinephrine during sodium nitroprusside-enhanced cardiop

145 ive measures including the use of oxygen and epinephrine (e.g. EpiPen), should be available to preven

146 currence, trigger avoidance, self-injectable epinephrine education, referral to an allergist, and be

147 Intracameral phenylephrine or epinephrine, either by direct injection or placement in

148 ese results suggest that exercise-stimulated epinephrine enhances resolution of acute inflammation in

149 ive towards the electrochemical detection of Epinephrine (Ep), in the presence of Serotonine-5-HT (S-

150 es - dopamine (DA), norepinephrine (NE), and epinephrine (EP).

151 /kg) (n = 6); and allergic rats treated with epinephrine (EPI) (10 microg/kg) (n = 6).

152 Both epinephrine (EPI) and norepinephrine (NE) could directly

153 h 5-thioglucose stimulated adrenal medullary epinephrine (Epi) release (3,153%) and feeding (400%), w

154 a or the host, such as autoinducer-3 (AI-3), epinephrine (Epi), and norepinephrine (NE).

155 roxyephedrine, HED), vesicular storage (C-11 epinephrine, EPI), and metabolic degradation (C-11 pheny

156 ters, i.e., dopamine (DA), serotonin (5-HT), epinephrine (Epn), and norepinephrine (Norepn), using sq

157 oups: 1) epinephrine, nebulized with 4 mg of epinephrine every 4 hours starting 1 hour post injury, n

158 scitation (n = 12; depth 1/3 chest diameter, epinephrine every 4 min).

159 ability analysis, and decreased 24-h urinary epinephrine excretion rate by 7%, without a significant

160 unomodulatory effects, we questioned whether epinephrine exerts proresolving actions on macrophages.

161 those with ACS), the decision to administer epinephrine for anaphylaxis can be difficult, and its be

162 ethionine (SAM) to catalyze the synthesis of epinephrine from norepinephrine.

163 ia point-source release generated transmural epinephrine gradients directly beneath the site of appli

164 ) in the dopamine group and four (7%) in the epinephrine group (p=0.033).

165 follow-up available (197/579 [34.0%] in the epinephrine group vs 219/648 [33.8%] in the control grou

166 -enhanced cardiopulmonary resuscitation plus epinephrine groups received 0.5 mg of epinephrine at 4.5

167 -enhanced cardiopulmonary resuscitation plus epinephrine groups, respectively; p=0.001).

168 vestigating the effectiveness of adrenaline (epinephrine), H1-antihistamines, systemic glucocorticost

169 Treatment with epinephrine had a significant reduction of the pulmonary

170 antigens and availability of self-injectable epinephrine has been a major focus of research teams, ad

171 Epinephrine has been associated with diverse human proce

172 ecommendations over whether use of nebulized epinephrine, hypertonic saline, or bronchodilators shoul

173 andomized controlled trial, standard dose of epinephrine improved overall survival but not neurologic

174 ll 31 patients with a fatal outcome received epinephrine in a titrated manner according to internatio

175 e needed to evaluate and optimize the use of epinephrine in cardiac arrest resuscitation, particularl

176 The fraction of intramuscular epinephrine in professional emergency treatment increase

177 me was to compare the effects of dopamine or epinephrine in severe sepsis on 28-day mortality; second

178 In the absence of epinephrine in the irrigation bottle, 12.4% of control e

179 We also suggest dobutamine or epinephrine in the presence of cardiogenic shock (2D) an

180 Epinephrine increased rate of matching beats from 35+/-4

181 from two trials showed that standard dose of epinephrine increased return of spontaneous circulation

182 Epinephrine increases myocardial contractility, decrease

183 can and European Americans for collagen- and epinephrine-induced aggregation, and in European America

184 e displayed decreased survival in a collagen/epinephrine-induced pulmonary embolism model of in vivo

185 ime, and reduced survival following collagen/epinephrine-induced pulmonary embolism were also observe

186 rther, 17dmiR-H1/H6 was severely impaired in epinephrine-induced reactivation in the rabbit ocular mo

187 nt mice were more resistant to collagen- and epinephrine-induced thromboembolism compared with wild-t

188 ury; however, the precise mechanism by which epinephrine influences inflammatory response and wound h

189 ygenation and metabolism, whereas continuous epinephrine infusion did not, compared with placebo.

190 d 40% O2: (1) during intravenous adrenaline (epinephrine) infusion at 320 ng kg(-1) min(-1) (320 ADR)

191 njury with HS and counterregulatory hormone (epinephrine) infusion profoundly stimulated adipocyte li

192 but there is no absolute contraindication to epinephrine injection in anaphylaxis.

193 patients who failed endoscopic therapy with epinephrine injection, clip, or thermal therapy.

194 Although epinephrine is essential for successful return of sponta

195 Epinephrine is frequently used as an inotropic and vasop

196 Epinephrine is life-saving in anaphylaxis; second-line m

197 thway deconvolution revealed that the DMR of epinephrine is originated mostly from the remodeling of

198 Epinephrine is routinely administered to sudden cardiac

199 Epinephrine is the first-line pharmacotherapy for unipha

200 Epinephrine is the first-line treatment for anaphylaxis.

201 Although adrenaline (epinephrine) is a cornerstone of initial anaphylaxis tre

202 Patients experiencing VIA received epinephrine less frequently than did cases with non-VIA.

203 Epinephrine levels during hypoglycemia were similar betw

204 the same dose rates, hemodynamic responses, epinephrine levels in the coronary sinus and systemic ci

205 Plasma epinephrine levels were normal and increased when the pa

206 xia resulting in profoundly increased plasma epinephrine levels.

207 proinflammatory macrophages is critical for epinephrine-mediated IL-6 production.

208 tagged PMNs in a murine skin wound, chronic, epinephrine-mediated stress was modeled by sustained del

209 While both norepinephrine and epinephrine mostly inhibit the angiogenic process in cut

210 -enhanced cardiopulmonary resuscitation plus epinephrine (n=10), and active compression-decompression

211 y, sheep were randomized into two groups: 1) epinephrine, nebulized with 4 mg of epinephrine every 4

212 of angiogenesis, the role of catecholamines (epinephrine, norepinephrine, and dopamine) is of interes

213 glucose levels (5.3 +/- 0.1 mmol/L), plasma epinephrine, norepinephrine, glucagon, cortisol, and gro

214 a resulted in significant blunting of plasma epinephrine, norepinephrine, glucagon, cortisol, and gro

215 lacebo resulted in significant reductions of epinephrine, norepinephrine, glucagon, growth hormone, c

216 (s)-coupled receptor agonists isoproterenol, epinephrine, norepinephrine, prostaglandin (PG) E(2), PG

217 resence of five neurotransmitters (dopamine, epinephrine, norepinephrine, serotonin, and histamine) a

218 So far, no direct role of epinephrine/norepinephrine in cellular iron homeostasis

219 Here we show that epinephrine/norepinephrine regulates iron homeostasis co

220 al aconitase (ACO2) activity are elevated by epinephrine/norepinephrine that are blocked by the antio

221 To restore the energy balance, epinephrine/norepinephrine-exposed cells may face higher

222 We demonstrate the role of epinephrine/norepinephrine-induced generation of reactiv

223 also observed in liver and muscle tissues of epinephrine/norepinephrine-injected mice.

224 (233/1558) compared with those with time to epinephrine of 5 minutes or less (1325/1558) had lower r

225 11 episodes (48%), the patient did not take epinephrine, of these 8 (73%) presented with local react

226 onectin secretion could not be stimulated by epinephrine or CL in adipocytes isolated from obese/type

227 with better adherence to timely delivery of epinephrine or defibrillation or higher rates of IHCA su

228 nduced pulmonary thromboembolism by collagen/epinephrine or long-chain polyphosphate, Klkb1(-/-) mice

229 and selective provocative drug testing with epinephrine or procainamide.

230 Epinephrine or the beta3-adrenergic receptor (AR) agonis

231 ; 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine) or local anesthesia (0.5% L-bupivacaine and

232 reatment of mouse hepatocytes with glucagon, epinephrine, or forskolin stimulated Rpn6 phosphorylatio

233 ation responses to serotonin (p = 0.007) and epinephrine (p = 0.004) compared with men.

234 L (3.3 mmol/L) with increases in both plasma epinephrine (P = 0.01) and glucagon (P = 0.01).

235 lar tachycardia was associated with a larger epinephrine/perfusion mismatch (n = 11).

236 wall thickening in myocardial segments with epinephrine/perfusion mismatch (n = 6).

237 High-risk patients had bolus epinephrine preordered and prepared for immediate admini

238 ression in the adrenal medulla and increased epinephrine production were also observed.

239 ide Y prevents a fasting-induced increase in epinephrine release and results in hypoglycemia in vivo.

240 of the sympathetic nervous system results in epinephrine release and subsequent suppression of the in

241 s the autonomic nervous system that controls epinephrine release from adrenal chromaffin cells and, c

242 catecholamine (CA; dopamine, norepinephrine, epinephrine) release within the social behavior neural n

243 Some epinephrine-resistant cases may play a role in our high

244 sponses in RH rats and restored the impaired epinephrine response to hypoglycemia in STZ-diabetic ani

245 ced an approximately 30% reduction in plasma epinephrine response together with reduced EGP and hypog

246 n the STZ group, consistent with the blunted epinephrine response.

247 abetic rats, and this augmented glucagon and epinephrine responses and hepatic glucose production dur

248 y, SGLT1 knockdown improved the glucagon and epinephrine responses in RH rats and restored the impair

249 Without a rise in glucagon, the epinephrine responses were much larger (DeltaAUC of 204

250 hed a nadir of approximately 2.0 mmol/L, and epinephrine rose to approximately 900 pg/mL.

251 0.017, 0.018, 0.019 and 0.020 ng mL(-1) for epinephrine (S/N = 3) in aqueous, blood serum, urine and

252 essed, glucagon secretion was recovered, and epinephrine secretion was improved after transplantation

253 Nebulized epinephrine should be considered for use in future clini

254 dingly, the mutant alpha2B -AR increases the epinephrine-stimulated calcium signaling.

255 Zyxin-deficient mice exhibit impaired epinephrine-stimulated VWF release, prolonged bleeding t

256 an important mechanistic link to explain how epinephrine stress exacerbates inflammation via increase

257 B reversal, no patients received atropine or epinephrine, suffered cardiac arrest, or died within 30

258 ation before receipt of a third 1-mg dose of epinephrine), survival rate at hospital discharge among

259 Compared with patients who did not receive epinephrine, the adjusted odds ratio of intact survival

260 nerated for arachidonic acid, ADP, collagen, epinephrine, Thrombin receptor activating-peptide, U4661

261 pronociceptive mediators, prostaglandin E2, epinephrine, TNFalpha, and interleukin-6, and the neurop

262 s that compared the current standard dose of epinephrine to placebo, high or low dose epinephrine, an

263 The addition of epinephrine to sodium nitroprusside-enhanced cardiopulmo

264 ylaxis and/or the need for repeated doses of epinephrine to treat anaphylaxis are risk factors for bi

265 ere was no difference in the requirement for epinephrine to treat reactions (P = .55).

266 a)ARs and hetero-alpha(2a)ARs activated with epinephrine to understand the role of Gbetagamma specifi

267 Epinephrine-treated macrophages displayed higher RvD1 le

268 Epinephrine treatment abolished the genotype differences

269 oughout 5 years of follow-up, whereas prompt epinephrine treatment for asystole/pulseless electric ac

270 ital survival with prompt defibrillation and epinephrine treatment in patients with in-hospital cardi

271 In productively infected neuronal cultures, epinephrine treatment significantly increased the levels

272 ity, the rate of 1-year survival with prompt epinephrine treatment was higher than with delayed treat

273 n increased similarly in working hearts upon epinephrine treatment, in skeletal muscles of exercising

274 t (</=5 minutes) versus delayed (>5 minutes) epinephrine treatment.

275 iderable systemic effects were observed with epinephrine treatment.

276 oxygenation index were also attenuated with epinephrine treatment.

277 als with meaningful patient outcomes; future epinephrine trials should evaluate dose and method of de

278 72], I(2)=0%, RD 12.2%, high-certainty), and epinephrine use (RR 2.21 [1.27-3.83], I(2)=0%, RD 4.5%,

279 There was no treatment-related epinephrine use in years 2 or 3.

280 ata from observational trials suggested that epinephrine use is associated with a worse outcome as co

281 anaphylaxis, allergic or adverse reactions, epinephrine use, and quality of life, meta-analysed by r

282 The percentage of patients receiving epinephrine, vasopressin, amiodarone, lidocaine, atropin

283 Bolus epinephrine was administered during 110 hypotension even

284 Intramuscular or intravenous epinephrine was administered significantly less often in

285 mine treatment were uncommon (0.21%), and no epinephrine was administered.

286 The use of epinephrine was associated with a survival odds ratio of

287 ived epinephrine, delay in administration of epinephrine was associated with decreased chance of surv

288 administration of peripheral or intraosseous epinephrine was associated with increased survival in th

289 Use of epinephrine was coded as yes/no and by dose (none, 1 mg,

290 ients who achieved ROSC, pre-hospital use of epinephrine was consistently associated with a lower cha

291 The DeltaAUC for epinephrine was greater with Pe than with Po (67 +/- 17

292 ired, whereas inhibition of cAMP increase by epinephrine was normal.

293 of H1 and H2 blockers, corticosteroids, and epinephrine was similar in the 2 treatment groups.

294 A 120-fold increase in epinephrine was subsequently observed that produced a tr

295 No epinephrine was used during cardiopulmonary resuscitatio

296 ic allergic reactions or reactions requiring epinephrine were observed.

297 n plus intrathoracic pressure regulator plus epinephrine were significantly increased versus active c

298 the 120 children enrolled (63, dopamine; 57, epinephrine) were similar.

299 Because exercise stimulates release of epinephrine, which has immunomodulatory effects, we ques

300 with the physiologic neurotransmitter (11)C-epinephrine, which is sensitive to metabolic degradation